

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

July 26, 2023

Brian Carrico Chief Executive Officer Neuraxis, Inc. 11550 N. Meridian Street, Suite 325 Carmel, IN 46032

Re: Neuraxis, Inc.
Amendment No. 7 to Registration Statement on Form S-1
Filed July 21, 2023
File No. 333-269179

Dear Brian Carrico:

We have reviewed your amended registration statement and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.

Amendment No. 7 to Form S-1 filed July 21, 2023

Cover Page

1. We note your statement on the cover page that the underwriter "is obligated to take and purchase all of the shares of common stock offered under this prospectus if any such shares are taken". We also note your statement on page 100 that the Selling Stockholder Shares "will not be sold through the underwriters" in the public offering. Please revise the cover page and your plan of distribution disclosure to reconcile these statements. We also note your statement on page 100 that the Selling Stockholder Shares may be resold "from time to time after the date of this prospectus". Please revise your disclosure to clearly state, if true, that selling shareholders may not commence their resale of shares until after the IPO closes. If this is not the case, please clarify and revise your disclosure accordingly. The timing of each offering should be clear and any related risks described.

Brian Carrico Neuraxis, Inc. July 26, 2023 Page 2

Please contact Cindy Polynice at 202-551-8707 or Laura Crotty at 202-551-3761 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Joe Lucosky, Esq.